Background:
MRI is one of the most important techniques to assess the treatment response of gliomas. However, differentiating tumor recurrence (TuR) from treatment effects (TrE) remains challenging.
Purpose:
To compare the diagnostic performance of MR diffusion-weighted imaging (DWI), arterial spin labeling (ASL), proton MR spectroscopy (MRS), and amide proton transfer (APT) imaging in differentiating between TuR and TrE in posttreatment glioma patients.
Study Type:
Prospective.
Population:
Thirty patients with suspected tumor progression.
Field Strength/sequence:
DWI, ASL, proton MRS, and APT imaging were performed at 3T MR.
Assessment:
MR indices, including ADC, relative cerebral blood flow (rCBF), ratios of Cho/Cr, Cho/NAA, and NAA/Cr and APT-weighted (APTw) effect were obtained from DWI, ASL, proton MRS, and APT imaging, respectively. Indices were measured in the contralateral normal-appearing white matter and lesions defined on the Gd-enhanced T w image. TuR or TrE was either determined histologically or clinically from longitudinal MRI follow-up for at least 6 months.
Statistical Tests:
The diagnostic performance of the indices was evaluated using Student's t-test, receiver operating characteristic (ROC) curve, and multivariate logistic regression analyses.
Results:
Among the 30 patients, 16 were diagnosed as having TuR and the rest having TrE. The recurrent tumors showed a significantly higher APTw effect (1.56 ± 1.14%) and rCBF (1.44 ± 0.61) compared with lesions representing treatment effects (-0.44 ± 1.34% and 0.72 ± 0.25, respectively, with P < 0.001). The areas under the curve (AUCs) were 0.87 and 0.90 for APTw and rCBF, respectively, in differentiating between TuR and TrE. Combining APTw and rCBF achieved a higher AUC of 0.93. MRS index ratios of Cho/Cr (P = 0.25), Cho/NAA (P = 0.16), and NAA/Cr (P = 0.86) and ADC (P = 0.37) showed no significant differences between TuR and TrE lesions, with AUCs lower than 0.70.
Data Conclusion:
Compared with DWI and MRS, ASL and APT imaging techniques showed better diagnostic capability in distinguishing TuR from TrE.
Level Of Evidence:
1 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2020;51:1154-1161.
Citing Articles
Radiomic feature reliability of amide proton transfer-weighted MR images acquired with compressed sensing at 3T.
Wu J, Huang Q, Shen Y, Guo P, Zhou J, Jiang S
Int J Imaging Syst Technol. 2024; 34(2).
PMID: 39185083
PMC: 11343505.
DOI: 10.1002/ima.23027.
Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.
Deng H, Zhang H, Huang B, Deng J, Luo S, Li W
Front Neurosci. 2024; 18:1424316.
PMID: 39148521
PMC: 11325484.
DOI: 10.3389/fnins.2024.1424316.
Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.
Essed R, Prysiazhniuk Y, Wamelink I, Azizova A, Keil V
Eur Radiol. 2024; 35(2):580-591.
PMID: 39134744
PMC: 11782315.
DOI: 10.1007/s00330-024-11004-y.
Amide proton transfer-weighted and arterial spin labeling imaging may improve differentiation between high-grade glioma recurrence and radiation-induced brain injury.
Chen L, Huang L, Zhang J, Li S, Li Y, Tang L
Heliyon. 2024; 10(11):e32699.
PMID: 38961946
PMC: 11219995.
DOI: 10.1016/j.heliyon.2024.e32699.
Velocity-Selective Arterial Spin Labeling Perfusion in Monitoring High Grade Gliomas Following Therapy: Clinical Feasibility at 1.5T and Comparison with Dynamic Susceptibility Contrast Perfusion.
Lambrecht S, Liu D, Dzaye O, Kamson D, Reis J, Liebig T
Brain Sci. 2024; 14(2).
PMID: 38391701
PMC: 10886779.
DOI: 10.3390/brainsci14020126.
APT weighted imaging in diffuse gliomas.
Nichelli L, Zaiss M, Casagranda S
BJR Open. 2023; 5(1):20230025.
PMID: 37942492
PMC: 10630980.
DOI: 10.1259/bjro.20230025.
Post-chemo-radiotherapy response and pseudo-progression evaluation on glioma cell types by multi-parametric magnetic resonance imaging: a prospective study.
Zamanian M, Abedi I, Danazadeh F, Amouheidari A, Shahreza B
BMC Med Imaging. 2023; 23(1):176.
PMID: 37932656
PMC: 10626695.
DOI: 10.1186/s12880-023-01135-x.
Reproducibility of APT-weighted CEST-MRI at 3T in healthy brain and tumor across sessions and scanners.
Wu Y, Wood T, Derks S, Pruis I, van der Voort S, Veldhuijzen van Zanten S
Sci Rep. 2023; 13(1):18115.
PMID: 37872418
PMC: 10593824.
DOI: 10.1038/s41598-023-44891-0.
The value of arterial spin labelling (ASL) perfusion MRI in the assessment of post-treatment progression in adult glioma: A systematic review and meta-analysis.
Alsulami T, Hyare H, Thomas D, Golay X
Neurooncol Adv. 2023; 5(1):vdad122.
PMID: 37841694
PMC: 10576519.
DOI: 10.1093/noajnl/vdad122.
Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma.
von Knebel Doeberitz N, Kroh F, Konig L, Boyd P, Grass S, Bauspiess C
Biomedicines. 2023; 11(9).
PMID: 37760790
PMC: 10525358.
DOI: 10.3390/biomedicines11092348.
Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.
Li A, Iv M
Front Radiol. 2023; 2:883293.
PMID: 37492665
PMC: 10365131.
DOI: 10.3389/fradi.2022.883293.
Multimodality MRI Radiomics Based on Machine Learning for Identifying True Tumor Recurrence and Treatment-Related Effects in Patients with Postoperative Glioma.
Ren J, Zhai X, Yin H, Zhou F, Hu Y, Wang K
Neurol Ther. 2023; 12(5):1729-1743.
PMID: 37488335
PMC: 10444917.
DOI: 10.1007/s40120-023-00524-2.
CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas.
Huang Q, Wu J, Le N, Shen Y, Guo P, Schreck K
Magn Reson Imaging. 2023; 102:222-228.
PMID: 37321378
PMC: 10528251.
DOI: 10.1016/j.mri.2023.06.003.
Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma.
Ohba S, Murayama K, Teranishi T, Kumon M, Nakae S, Yui M
Cancers (Basel). 2023; 15(3).
PMID: 36765909
PMC: 9913574.
DOI: 10.3390/cancers15030952.
Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas.
Jiang S, Guo P, Heo H, Zhang Y, Wu J, Jin Y
NMR Biomed. 2022; 36(1):e4824.
PMID: 36057449
PMC: 10502874.
DOI: 10.1002/nbm.4824.
Differentiation between glioma recurrence and treatment effects using amide proton transfer imaging: A mini-Bayesian bivariate meta-analysis.
Chen K, Jiang X, Deng L, She H
Front Oncol. 2022; 12:852076.
PMID: 35978813
PMC: 9376615.
DOI: 10.3389/fonc.2022.852076.
Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients.
Guo P, Unberath M, Heo H, Eberhart C, Lim M, Blakeley J
Neuroimage Clin. 2022; 35:103121.
PMID: 35905666
PMC: 9421489.
DOI: 10.1016/j.nicl.2022.103121.
Analysis of DWI in the classification of glioma pathology and its therapeutic application in clinical surgery: a case-control study.
Wu J, Su R, Qiu D, Cheng X, Li L, Huang C
Transl Cancer Res. 2022; 11(4):805-812.
PMID: 35571647
PMC: 9091004.
DOI: 10.21037/tcr-22-114.
Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors.
Zhou J, Zaiss M, Knutsson L, Sun P, Ahn S, Aime S
Magn Reson Med. 2022; 88(2):546-574.
PMID: 35452155
PMC: 9321891.
DOI: 10.1002/mrm.29241.
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange....
Booth T, Wiegers E, Warnert E, Schmainda K, Riemer F, Nechifor R
Front Oncol. 2022; 11:811425.
PMID: 35340697
PMC: 8948428.
DOI: 10.3389/fonc.2021.811425.